The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial.

Follicum also works in the diabetes space, where the drug candidate FOL-014 has demonstrated encouraging effects on insulin production in the pre-clinical phase.

The company was founded in 2011, and is based in Lund, Sweden. Follicum has been listed on the Swedish small-cap exchange Aktietorget since 2014.